Amalgamated Bank Sells 945 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS)

Amalgamated Bank reduced its stake in BioLife Solutions, Inc. (NASDAQ:BLFS) by 6.0% during the fourth quarter, HoldingsChannel.com reports. The firm owned 14,723 shares of the medical equipment provider’s stock after selling 945 shares during the quarter. Amalgamated Bank’s holdings in BioLife Solutions were worth $239,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the stock. Nisa Investment Advisors LLC raised its holdings in BioLife Solutions by 167.2% in the 4th quarter. Nisa Investment Advisors LLC now owns 1,630 shares of the medical equipment provider’s stock worth $26,000 after acquiring an additional 1,020 shares during the last quarter. GAMMA Investing LLC purchased a new position in BioLife Solutions in the 4th quarter worth approximately $41,000. Allspring Global Investments Holdings LLC raised its stake in BioLife Solutions by 88.4% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 11,346 shares of the medical equipment provider’s stock valued at $157,000 after buying an additional 5,324 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in BioLife Solutions by 8.1% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 15,622 shares of the medical equipment provider’s stock valued at $216,000 after buying an additional 1,164 shares during the last quarter. Finally, Dark Forest Capital Management LP purchased a new stake in BioLife Solutions during the 3rd quarter valued at $223,000. 93.24% of the stock is owned by institutional investors.

BioLife Solutions Trading Up 0.9 %

Shares of BLFS stock opened at $21.88 on Thursday. BioLife Solutions, Inc. has a 1 year low of $8.92 and a 1 year high of $24.50. The firm has a fifty day moving average price of $18.22 and a 200-day moving average price of $16.61. The company has a debt-to-equity ratio of 0.05, a current ratio of 2.89 and a quick ratio of 1.77. The company has a market cap of $1.01 billion, a price-to-earnings ratio of -15.41 and a beta of 1.69.

BioLife Solutions (NASDAQ:BLFS) last issued its earnings results on Thursday, May 9th. The medical equipment provider reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.06. The company had revenue of $31.73 million during the quarter, compared to the consensus estimate of $29.30 million. BioLife Solutions had a negative net margin of 45.84% and a negative return on equity of 12.89%. During the same quarter in the prior year, the firm posted ($0.27) EPS. As a group, equities analysts predict that BioLife Solutions, Inc. will post -0.5 earnings per share for the current year.

Insider Buying and Selling

In other BioLife Solutions news, CMO Todd Berard sold 10,000 shares of the stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $15.67, for a total transaction of $156,700.00. Following the completion of the transaction, the chief marketing officer now owns 129,644 shares of the company’s stock, valued at approximately $2,031,521.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO Greef Roderick De sold 7,249 shares of the company’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $16.60, for a total transaction of $120,333.40. Following the sale, the chief executive officer now directly owns 461,854 shares in the company, valued at approximately $7,666,776.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CMO Todd Berard sold 10,000 shares of the company’s stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $15.67, for a total transaction of $156,700.00. Following the sale, the chief marketing officer now owns 129,644 shares in the company, valued at $2,031,521.48. The disclosure for this sale can be found here. In the last quarter, insiders sold 33,869 shares of company stock valued at $561,733. Company insiders own 2.70% of the company’s stock.

Analysts Set New Price Targets

BLFS has been the subject of a number of research reports. Benchmark upgraded shares of BioLife Solutions from a “neutral” rating to a “buy” rating and set a $25.00 target price for the company in a research note on Monday, May 13th. Jefferies Financial Group initiated coverage on shares of BioLife Solutions in a research note on Thursday, April 4th. They set a “buy” rating and a $22.00 target price for the company. Finally, StockNews.com upgraded shares of BioLife Solutions to a “sell” rating in a research note on Friday, May 10th. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. According to data from MarketBeat.com, BioLife Solutions has a consensus rating of “Moderate Buy” and an average target price of $23.67.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.